American Century Companies Inc. Sells 152,405 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

American Century Companies Inc. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,641,441 shares of the biopharmaceutical company’s stock after selling 152,405 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 0.4% of American Century Companies Inc.’s holdings, making the stock its 21st largest position. American Century Companies Inc.’s holdings in Alnylam Pharmaceuticals were worth $748,500,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after purchasing an additional 75,936 shares during the last quarter. Orbis Allan Gray Ltd increased its position in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Norges Bank bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $662,837,000. Finally, Groupama Asset Managment boosted its position in Alnylam Pharmaceuticals by 0.5% in the second quarter. Groupama Asset Managment now owns 1,548,385 shares of the biopharmaceutical company’s stock valued at $504,913,000 after buying an additional 8,246 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,959 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the sale, the executive vice president owned 31,769 shares of the company’s stock, valued at $9,850,931.52. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,578 shares of company stock worth $12,416,105 in the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:ALNY opened at $332.92 on Friday. The business’s 50 day moving average is $360.54 and its 200 day moving average is $418.95. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The stock has a market cap of $44.15 billion, a price-to-earnings ratio of 194.69 and a beta of 0.35. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.65) earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on ALNY shares. Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.